In 588 patients with PD-L1-positive (CPS ≥5) resectable gastric or GOJ adenocarcinoma, perioperative serplulimab with neoadjuvant SOX improved event-free survival vs perioperative SOX (median not reached vs 35·9 months; HR 0·73), with less grade ≥3 toxicity (47% vs 59%).
RCTn = 588
Shen et al. Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study